News
Celyad Announces Third Quarter 2018 Business Update
Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting
Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting
Celyad to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH Annual Meeting
Celyad to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH Annual Meeting
Celyad Announces Exclusive Agreement for Horizon Discovery’s shRNA Platform to Develop Next-Generation Allogeneic CAR-T Therapies
Celyad Announces Exclusive Agreement for Horizon Discovery’s shRNA Platform to Develop Next-Generation Allogeneic CAR-T Therapies
Transparency notification of Victory Capital Management Inc. (Article 14 of the Law of 2 May 2007)
Transparency notification of Victory Capital Management Inc. (Article 14 of the Law of 2 May 2007)
Celyad Reports First Half 2018 Financial Results and Operational Progress
Celyad Reports First Half 2018 Financial Results and Operational Progress
Celyad Appoints Filippo Petti as Chief Financial Officer
Celyad Appoints Filippo Petti as Chief Financial Officer
Dr. Margo Roberts joins Celyad’s Board of Directors and Scientific Committee
Dr. Margo Roberts joins Celyad’s Board of Directors and Scientific Committee
Celyad Announces FDA Acceptance of IND Application for CYAD-101, a First-in-Class Non-Gene Edited Allogeneic CAR-T Candidate
Celyad Announces FDA Acceptance of IND Application for CYAD-101, a First-in-Class Non-Gene Edited Allogeneic CAR-T Candidate
Celyad announces pricing of $47.3 million global offering
Celyad announces pricing of $47.3 million global offering
Celyad announces launch of proposed global offering
Celyad announces launch of proposed global offering